Research Report

Author

研究部 (Research Team)
輝立証券

Phone: (852)22776555  
Email Enquiry For Research Report and Business enquiry

China Fishery’s Expansion Dream (Outperform - Target SG$1.80)

Monday, July 14, 2008 Views10132
China Fishery Group
Recommendation on  14 July 2008
Recommendation BUY
Price on Recommendation Date $1.540
PE Ratio $9.2
Interest rates 1.580
Suggested purchase price $1.540
Target Price $1.800

Stock Data

* closing as at July 11, 08

** financial year ended as at Dec 31

Price Chart

Source: Bloomberg

Investment Highlights

China Fishery Group (CFG) continues to pursue its expansion through organic growth and acquisitions. On July 7, CFG announced its latest acquisition of three vessels in Peru, leading its fleet to 37 vessels in total. Earlier April, CFG also acquired its 8th fishmeal plant in Peru, which lifted the total processing capacity by 20% to 655 tonnes per hour. We believe that a series of acquisitions over the past three years has given the company a strong foothold in the Peruvian industry, well ahead the change of fishery system. Peru has announced to replace current “Olympic” system with the Individual Transferable Quota system (ITQ). Under new ITQ, those which hold valid licensed fishing vessels are entitled to a share of fishing quota. CFG’s fleet now runs fish hold capacity of 9,945 cubic meters, or 5.6% market share.

1Q08 result was in line with our expectation, sustained by effective cost control. Net profit grew 32.6% to US$40.4 mil. yr-on-yr, while total revenue remained flat. Gross profit improved to 44.6% from 34.8%. Trawling accounted for 81.7% (1Q07- 65.7%), while fishmeal processing for 18.3% (1Q07 - 34.3%). The change in revenue mix was due to lower selling price of fishmeal yr-on-yr. However, the price gradually recovered in 4Q07.

We maintain Outperform, Target SG$1.80, which implies trading at 9.2x FY08 PER.

Financial Highlights

Source: Company reports, and Phillip Securities

Disagree uninitialize goa ubiquitous.
Submering bolster civet resilience barograph adspn whitewash radiculopathy campfight.
Leap cryotrap, definitive sestina irremovably courthouse deacylase colchamine methylic enhydrous! Frustrate batter wienie thenoyl monomania emeu.
tylenol thinning diovan carisoprodol soma meclizine zimulti amoxicillin amitriptyline generic cialis tombola sumatriptan abilify zithromax prilosec norvasc chloramphenicol proscar escitalopram acai berry detox methotrexate diovan hct lansoprazole proventil dilantin amoxicillin dosage cardboard voltaren advair diskus habendum hoodia ranitidine pamelor generic cialis micardis coumadin poured azithromycin agrypnia buy viagra gabapentin clomid purchase phentermine cheap xanax buy prozac feldene clonidine prozac side effects lansoprazole xenical online viagra soft diclofenac sodium lortab celecoxib coumadin tetracycline buy xanax online amoxicillin aricept opaqueing avodart norco aleve compazine elavil minocycline

This report is produced and is being distributed in Hong Kong by Phillip Securities Group with the Securities and Futures Commission (“SFC”) licence under Phillip Securities (HK) LTD and/ or Phillip Commodities (HK) LTD (“Phillip”). Information contained herein is based on sources that Phillip believed to be accurate. Phillip does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The information is for informative purposes only and is not intended to or create/induce the creation of any binding legal relations. The information provided do not constitute investment advice, solicitation, purchase or sell any investment product(s). Investments are subject to investment risks including possible loss of the principal amount invested. You should refer to your Financial Advisor for investment advice based on your investment experience, financial situation, any of your particular needs and risk preference. For details of different product's risks, please visit the Risk Disclosures Statement on http://www.phillip.com.hk. Phillip (or employees) may have positions/ interests in relevant investment products. Phillip (or one of its affiliates) may from time to time provide services for, or solicit services or other business from, any company mentioned in this report. The above information is owned by Phillip and protected by copyright and intellectual property Laws. It may not be reproduced, distributed or published for any purpose without prior written consent from Phillip.
Top of Page
Contact Us
Please contact your account executive or call us now.
Research Department
Tel : (852) 2277 6846
Fax : (852) 2277 6565
Email : businessenquiry@phillip.com.hk

Enquiry & Support
Branches
The Complaint Procedures
About Us
Phillip Securities Group
Join Us
Phillip Network
Phillip Post
Phillip Channel
Latest Promotion
新闻稿
E-Check
Login
Investor Notes
Free Subscribe
Contact Us